Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The management of malignant hypercalcaemia

J Watters1, G Gerrand, D Dodwell

  • 1Yorkshire Regional Centre for Cancer Treatment, Cookridge Hospital, Leeds, England.

Drugs
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world obesity prevalence and history in 79 271 patients receiving systemic anticancer therapy across 13 cancer types in England (2013-2023).

ESMO real world data and digital oncology·2026
Same author

The National Audit of Metastatic Breast Cancer (NAoMe): Sharing Key Findings and Recommendations From the 2025 State of the Nation Report.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumour.

NPJ breast cancer·2026
Same author

Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: a population-based retrospective cohort study.

ESMO real world data and digital oncology·2026
Same author

Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Discrepancy between mammographic and pathological sizing of screen-detected DCIS: Risk factors and impact on ipsilateral recurrence rates.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025

Malignant hypercalcaemia management has improved with bisphosphonates like clodronate and pamidronate as effective intravenous treatments. While well-tolerated, their precise mechanisms and pharmacokinetics require further investigation.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Malignant hypercalcaemia is a frequent complication encountered by cancer clinicians.
  • Historically challenging, its management has seen significant advancements over the past decade.
  • Modern therapeutic strategies have rendered the condition largely manageable.

Purpose of the Study:

  • To review the current management of malignant hypercalcaemia.
  • To highlight the role of pharmacological agents, particularly bisphosphonates.
  • To discuss the established efficacy and limitations in understanding bisphosphonate action.

Main Methods:

  • Review of current clinical practices and pharmacological agents for malignant hypercalcaemia.
  • Focus on the established role of bisphosphonate drugs, specifically clodronate and pamidronate.

Related Experiment Videos

  • Assessment of bisphosphonate efficacy, tolerability, and administration routes (intravenous).

    • Main Results:

    • Bisphosphonate drugs, including clodronate and pamidronate, are the cornerstone of contemporary malignant hypercalcaemia management.
    • Intravenous administration of bisphosphonates demonstrates effectiveness and good tolerability.
    • Significant gaps remain in understanding the detailed mechanisms of action and pharmacokinetics of bisphosphonates.

    Conclusions:

    • Modern treatment, primarily utilizing bisphosphonates, effectively manages malignant hypercalcaemia.
    • Bisphosphonates are confirmed as the mainstay therapy due to their efficacy and tolerability.
    • Further research is needed to elucidate the pharmacokinetics and mechanisms of action of bisphosphonates.